申请人:Ciba-Geigy Corporation
公开号:US04500542A1
公开(公告)日:1985-02-19
The invention relates to novel dioxaheterocyclic compounds of the formula I ##STR1## in which R.sub.1 represents an unsubstituted or substituted aromatic or heteroaromatic radical or an unsubstituted or lower alkylated, mono- or bi-cyclic cycloaliphatic hydrocarbon radical or an .alpha.-branched aliphatic hydrocarbon radical, each of R.sub.2 and R.sub.3, independently of the other, represents hydrogen or lower alkyl, and each of R.sub.4 and R.sub.5, independently of the other, represents hydrogen, lower alkyl or halogen, and A represents the radical --O--R.sub.6, wherein R.sub.6 represents hydrogen or an unsubstituted or substituted aliphatic or araliphatic hydrocarbon radical or A represents the radical ##STR2## in which each of R.sub.7 and R.sub.8, independently of the other, represents hydrogen or lower alkyl, or R.sub.7 and R.sub.8 are bonded to one another and, together with the adjacent nitrogen atom, represent unsubstituted or lower alkyl-substituted tetra- to hexa-methyleneimino or 4-morpholinyl, and the divalent radical in formula I is either in the 4,5- or the 5,6-position and correspondingly R.sub.4 and R.sub.5 are in positions 6 and 7, or 4 and 7, respectively, of the benzodioxole skeleton, to salts of compounds of the formula I in which A represents OR.sub.6 wherein R.sub.6 represents hydrogen, with bases, as well as acid addition salts of compounds of the formula I in which the radical R.sub.1 is of basic character, and to pharmaceutical compositions containing them. These novel substances have a diuretic activity and, in addition, a uricosuric activity, and can be administered, according to the invention, preferably in the form of corresponding pharmaceutical compositions, to mammals for the treatment of oedema and hypertension.
该发明涉及公式I的新颖二氧杂杂环化合物,其中R.sub.1代表未取代或取代的芳香或杂芳基团,或未取代或较低烷基化的单环或双环脂环烷基碳氢基团,或α-支链脂环烷基碳氢基团,R.sub.2和R.sub.3各自独立地代表氢或较低烷基,R.sub.4和R.sub.5各自独立地代表氢、较低烷基或卤素,A代表基团--O--R.sub.6,其中R.sub.6代表氢或未取代或取代的脂肪或芳基脂基碳氢基团,或A代表基团,其中R.sub.7和R.sub.8各自独立地代表氢或较低烷基,或R.sub.7和R.sub.8相互连接,并与相邻的氮原子一起表示未取代或较低烷基取代的四-至六亚甲基亚胺基或4-吗啉基,公式I中的二价基团位于4,5-或5,6-位置,相应地R.sub.4和R.sub.5位于苯二氧杂环骨架的6和7位置或4和7位置,以及公式I中A代表OR.sub.6的化合物的盐,其中R.sub.6代表氢,与碱形成的盐,以及公式I中基团R.sub.1具有碱性质的化合物的酸盐,以及含有它们的药物组合物。这些新颖物质具有利尿活性以及利尿酸排泄活性,并且可以根据该发明优选以相应的药物组合物的形式给哺乳动物治疗水肿和高血压。